anthralin has been researched along with Alopecia Circumscripta in 38 studies
Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.
anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective randomized clinical trial was conducted on 50 patients with Alopecia areata who received DPCP alone (group D) or in combination with anthralin (group D/A)." | 9.41 | A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata. ( Abedini, R; Aryanian, Z; Daneshmand, R; Ghandi, N; Hatami, P; Nasimi, M; Vance, TM, 2021) |
| "A PRISMA-compliant systematic review of seven electronic databases was searched by the terms "alopecia areata," "pediatric," "topical immunotherapy," "Anthralin," and "light therapy" from inception until March 2021." | 9.22 | A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low-level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow-up based ( Behrangi, E; Dodangeh, M; Ghassemi, M; Goodarzi, A; Najar Nobari, N; Roohaninasab, M; Sadeghzadeh-Bazargan, A; Seirafianpour, F, 2022) |
| "The goal of this study was to determine the efficacy, tolerability, and safety of azelaic acid treatment in patients with patchy alopecia areata (AA) in comparison with anthralin (dithranol) treatment." | 9.11 | Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. ( Arican, O; Sasmaz, S, 2005) |
| "Topical anthralin application producing a brisk irritant contact dermatitis has been reported to have therapeutic benefit in alopecia areata." | 9.05 | Anthralin therapy for alopecia areata. ( Nelson, DA; Spielvogel, RL, 1985) |
| "The aim of this study was to examine effectiveness of combination therapy with both topical immunotherapy with squaric acid dibutylester or diphenylcyclopropenone and anthralin in the treatment of refractory alopecia areata." | 7.96 | Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata. ( Hino, H; Kagami, S; Kishi, Y, 2020) |
| "Contact immunotherapy with diphenylcyclopropenone (DPCP) and anthralin is considered the treatment option for extensive alopecia areata (AA) unresponsive to DPCP immunotherapy alone." | 7.91 | Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series. ( Abedini, R; Ghandi, N; Mirshamsi, A; Nasimi, M; Seirafi, H; Shakoei, S, 2019) |
| "Medical records of 37 patients with alopecia areata who were started on topical anthralin before age 17 were reviewed for efficacy and safety data." | 7.88 | Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients. ( Bergfeld, WF; Ratnaparkhi, R; Wang, S; Wu, SZ, 2018) |
| "Anthralin is a widely used topical anti-psoriatic drug that may have an immunomodulating effect on alopecia areata (AA) as it does in psoriasis." | 7.72 | Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. ( Cao, L; Lui, H; Shapiro, J; Sundberg, JP; Tang, L, 2004) |
| "5% anthralin was used to treat 51 patients with severe treatment-resistant alopecia areata." | 7.68 | Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. ( DeVillez, RL; Fiedler, VC; Metzler, C; Szpunar, GJ; Wendrow, A, 1990) |
| "Anthralin 1% is an effective therapy for AA and should be continued at least 9 months." | 6.84 | Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata. ( Balevi, A; Özdemir, M, 2017) |
| "A prospective randomized clinical trial was conducted on 50 patients with Alopecia areata who received DPCP alone (group D) or in combination with anthralin (group D/A)." | 5.41 | A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata. ( Abedini, R; Aryanian, Z; Daneshmand, R; Ghandi, N; Hatami, P; Nasimi, M; Vance, TM, 2021) |
| "A PRISMA-compliant systematic review of seven electronic databases was searched by the terms "alopecia areata," "pediatric," "topical immunotherapy," "Anthralin," and "light therapy" from inception until March 2021." | 5.22 | A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low-level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow-up based ( Behrangi, E; Dodangeh, M; Ghassemi, M; Goodarzi, A; Najar Nobari, N; Roohaninasab, M; Sadeghzadeh-Bazargan, A; Seirafianpour, F, 2022) |
| "The goal of this study was to determine the efficacy, tolerability, and safety of azelaic acid treatment in patients with patchy alopecia areata (AA) in comparison with anthralin (dithranol) treatment." | 5.11 | Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. ( Arican, O; Sasmaz, S, 2005) |
| "Topical anthralin application producing a brisk irritant contact dermatitis has been reported to have therapeutic benefit in alopecia areata." | 5.05 | Anthralin therapy for alopecia areata. ( Nelson, DA; Spielvogel, RL, 1985) |
| "The aim of this study was to examine effectiveness of combination therapy with both topical immunotherapy with squaric acid dibutylester or diphenylcyclopropenone and anthralin in the treatment of refractory alopecia areata." | 3.96 | Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata. ( Hino, H; Kagami, S; Kishi, Y, 2020) |
| "Contact immunotherapy with diphenylcyclopropenone (DPCP) and anthralin is considered the treatment option for extensive alopecia areata (AA) unresponsive to DPCP immunotherapy alone." | 3.91 | Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series. ( Abedini, R; Ghandi, N; Mirshamsi, A; Nasimi, M; Seirafi, H; Shakoei, S, 2019) |
| "Medical records of 37 patients with alopecia areata who were started on topical anthralin before age 17 were reviewed for efficacy and safety data." | 3.88 | Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients. ( Bergfeld, WF; Ratnaparkhi, R; Wang, S; Wu, SZ, 2018) |
| "Anthralin is a widely used topical anti-psoriatic drug that may have an immunomodulating effect on alopecia areata (AA) as it does in psoriasis." | 3.72 | Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. ( Cao, L; Lui, H; Shapiro, J; Sundberg, JP; Tang, L, 2004) |
| "5% anthralin was used to treat 51 patients with severe treatment-resistant alopecia areata." | 3.68 | Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. ( DeVillez, RL; Fiedler, VC; Metzler, C; Szpunar, GJ; Wendrow, A, 1990) |
| "Anthralin 1% is an effective therapy for AA and should be continued at least 9 months." | 2.84 | Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata. ( Balevi, A; Özdemir, M, 2017) |
| "Alopecia areata is a form of autoimmune hair loss affecting both children and adults." | 2.52 | Alopecia areata: Part 2: treatment. ( Donovan, JC; Spano, F, 2015) |
| "Treatment of alopecia areata is dependent on age of patient as well as the extent and duration of scalp involvement." | 2.49 | Current treatment of alopecia areata. ( Shapiro, J, 2013) |
| "Alopecia areata is regarded as a tissue-restricted autoimmune disease of hair follicles in which follicular activity is arrested because of the continued activity of lymphocytic infiltrates." | 2.42 | Old wine in new bottles: reviving old therapies for alopecia areata using rodent models. ( Lui, H; Shapiro, J; Sundberg, JP; Tang, L, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (15.79) | 18.7374 |
| 1990's | 4 (10.53) | 18.2507 |
| 2000's | 9 (23.68) | 29.6817 |
| 2010's | 12 (31.58) | 24.3611 |
| 2020's | 7 (18.42) | 2.80 |
| Authors | Studies |
|---|---|
| Behrangi, E | 1 |
| Roohaninasab, M | 1 |
| Sadeghzadeh-Bazargan, A | 1 |
| Najar Nobari, N | 1 |
| Ghassemi, M | 1 |
| Seirafianpour, F | 1 |
| Goodarzi, A | 1 |
| Dodangeh, M | 1 |
| Mathachan, SR | 1 |
| Sardana, K | 2 |
| Khurana, A | 1 |
| Reyes-Hadsall, S | 1 |
| Drake, L | 1 |
| Han, JJ | 1 |
| Lee, KJ | 1 |
| Zhou, G | 1 |
| Mostaghimi, A | 1 |
| Huang, KP | 1 |
| Kagami, S | 1 |
| Kishi, Y | 1 |
| Hino, H | 1 |
| Hon, KL | 1 |
| Luk, DCK | 1 |
| Leung, AKC | 1 |
| Ng, C | 1 |
| Loo, SKF | 1 |
| Benezeder, T | 1 |
| Gehad, A | 1 |
| Patra, V | 1 |
| Clark, R | 1 |
| Wolf, P | 1 |
| Ghandi, N | 2 |
| Daneshmand, R | 1 |
| Hatami, P | 1 |
| Abedini, R | 2 |
| Nasimi, M | 2 |
| Aryanian, Z | 1 |
| Vance, TM | 1 |
| Ngwanya, MR | 1 |
| Gray, NA | 1 |
| Gumedze, F | 1 |
| Ndyenga, A | 1 |
| Khumalo, NP | 1 |
| Murad, A | 1 |
| Bergfeld, W | 1 |
| Gupta, A | 1 |
| Gautam, RK | 1 |
| Wu, SZ | 1 |
| Wang, S | 1 |
| Ratnaparkhi, R | 1 |
| Bergfeld, WF | 1 |
| Daunton, A | 1 |
| Harries, M | 1 |
| Mirshamsi, A | 1 |
| Shakoei, S | 1 |
| Seirafi, H | 1 |
| Ibrahim, SA | 1 |
| Esawy, AM | 1 |
| Abdelshafy, AS | 1 |
| Shapiro, J | 6 |
| Durdu, M | 1 |
| Özcan, D | 1 |
| Baba, M | 1 |
| Seçkin, D | 1 |
| Perera, E | 1 |
| Yip, L | 1 |
| Sinclair, R | 1 |
| Spano, F | 1 |
| Donovan, JC | 1 |
| Özdemir, M | 1 |
| Balevi, A | 1 |
| Mukherjee, N | 1 |
| Burkhart, CN | 1 |
| Morrell, DS | 1 |
| Tang, L | 3 |
| Cao, L | 2 |
| Pelech, S | 1 |
| Lui, H | 3 |
| Sundberg, JP | 2 |
| MacDonald Hull, SP | 1 |
| Wood, ML | 1 |
| Hutchinson, PE | 1 |
| Sladden, M | 1 |
| Messenger, AG | 1 |
| Sasmaz, S | 1 |
| Arican, O | 1 |
| Wasserman, D | 1 |
| Guzman-Sanchez, DA | 1 |
| Scott, K | 1 |
| McMichael, A | 1 |
| de Groot, AC | 2 |
| Nater, JP | 2 |
| Bleumink, E | 1 |
| de Jong, MC | 2 |
| Price, VH | 2 |
| Bernard, P | 1 |
| Arnoult-Coudoux, E | 1 |
| Epstein, E | 1 |
| Wiseman, MC | 1 |
| Schmoeckel, C | 1 |
| Weissmann, I | 1 |
| Plewig, G | 1 |
| Braun-Falco, O | 1 |
| Fiedler, VC | 1 |
| Wendrow, A | 1 |
| Szpunar, GJ | 1 |
| Metzler, C | 1 |
| DeVillez, RL | 1 |
| Fiedler-Weiss, VC | 1 |
| Buys, CM | 1 |
| Oranje, AP | 1 |
| Peereboom-Wynia, JD | 1 |
| de Raeymaecker, DM | 1 |
| Nelson, DA | 1 |
| Spielvogel, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation[NCT03473600] | Phase 4 | 40 participants (Anticipated) | Interventional | 2018-11-30 | Not yet recruiting | ||
| Microarray Analysis of Scalp Biopsies in Subjects With Androgenetic Alopecia Before and After the Use of Topical Minoxidil[NCT01309191] | 14 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata[NCT00999869] | 20 participants (Anticipated) | Interventional | 2009-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for anthralin and Alopecia Circumscripta
| Article | Year |
|---|---|
A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low-level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow-up based
Topics: Administration, Topical; Alopecia Areata; Anthralin; Child; Dermatitis, Contact; Duration of Therapy | 2022 |
Childhood Alopecia Areata: An Overview of Treatment and Recent Patents.
Topics: Adrenal Cortex Hormones; Alopecia Areata; Anthralin; Child; Humans; Immunotherapy; Minoxidil; Patent | 2020 |
Treatment for facial alopecia areata: A systematic review with evidence-based analysis.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Alopecia Areata; Anthralin; Bimatoprost; Cyclopropanes; Derma | 2018 |
Current treatment of alopecia areata.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Alopecia Areata; Anthralin; Cyclobutanes; Cyclop | 2013 |
Alopecia areata.
Topics: Administration, Topical; Adrenal Cortex Hormones; Alopecia Areata; Anthralin; Autoimmunity; Cyclopro | 2015 |
Alopecia areata: Part 2: treatment.
Topics: Adult; Alopecia Areata; Anthralin; Child; Cyclopropanes; Dermatologic Agents; Humans; Immunosuppress | 2015 |
Treatment of alopecia areata in children.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Alopecia Areata; Anthralin; Child; Child, Prescho | 2009 |
Cytokines and signal transduction pathways mediated by anthralin in alopecia areata-affected Dundee experimental balding rats.
Topics: Alopecia Areata; Animals; Anthralin; Cytokines; Hair Follicle; Rats; Rats, Mutant Strains; Signal Tr | 2003 |
Old wine in new bottles: reviving old therapies for alopecia areata using rodent models.
Topics: Alopecia Areata; Animals; Anthralin; Disease Models, Animal; Mechlorethamine; Rodentia | 2003 |
Alopecia areata.
Topics: Adult; Alopecia Areata; Anthralin; Child; Dermatologic Agents; Glucocorticoids; Humans; Immunotherap | 2007 |
Hair regrowth. Therapeutic agents.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia; Alopecia Areata; Androgen Antagon | 1998 |
Treatment of hair loss.
Topics: 5-alpha Reductase Inhibitors; Administration, Topical; Alopecia; Alopecia Areata; Anthralin; Anti-In | 1999 |
[Alopecia areata: management strategy].
Topics: Adolescent; Adult; Age Factors; Alopecia Areata; Anthralin; Anti-Inflammatory Agents; Child; Humans; | 2001 |
Therapeutic approach to alopecia areata.
Topics: Administration, Topical; Adrenal Cortex Hormones; Age Factors; Algorithms; Alopecia Areata; Anthrali | 1999 |
5 trials available for anthralin and Alopecia Circumscripta
| Article | Year |
|---|---|
A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata.
Topics: Adolescent; Adult; Age of Onset; Alopecia Areata; Anthralin; Chronic Disease; Cyclopropanes; Drug Th | 2021 |
Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata.
Topics: Administration, Topical; Adolescent; Alopecia Areata; Anthralin; Child; Chronic Disease; Dermatologi | 2017 |
Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study.
Topics: Administration, Topical; Adult; Alopecia Areata; Anthralin; Anti-Inflammatory Agents; Dermatologic A | 2005 |
Evaluation of anthralin in the treatment of alopecia areata.
Topics: Administration, Topical; Adult; Alopecia Areata; Anthralin; Clinical Trials as Topic; Female; Hair; | 1987 |
Anthralin therapy for alopecia areata.
Topics: Administration, Topical; Alopecia Areata; Anthracenes; Anthralin; Clinical Trials as Topic; Humans | 1985 |
19 other studies available for anthralin and Alopecia Circumscripta
| Article | Year |
|---|---|
A study examining the combination of methotrexate and leflunomide with topical anthralin in pediatric alopecia areata-a possible steroid-free regimen with diverse mechanistic actions.
Topics: Administration, Topical; Alopecia Areata; Anthralin; Child; Humans; Leflunomide; Methotrexate | 2022 |
Shared Decision-Making, Therapeutic Choice, and Decisional Regret in Patients With Alopecia Areata.
Topics: Alopecia Areata; Anthralin; Biological Products; Cross-Sectional Studies; Decision Making; Emotions; | 2022 |
Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.
Topics: Administration, Topical; Alopecia Areata; Anthralin; Humans; Immunotherapy; Japan; Treatment Outcome | 2020 |
Induction of IL-1β and antimicrobial peptides as a potential mechanism for topical dithranol.
Topics: Alopecia Areata; Animals; Anthralin; Antimicrobial Peptides; Cytokines; Dermatologic Agents; Humans; | 2021 |
Higher concentrations of dithranol appear to induce hair growth even in severe alopecia areata.
Topics: Administration, Topical; Alopecia Areata; Anthralin; Dermatologic Agents; Dose-Response Relationship | 2017 |
Recalcitrant alopecia areata responsive to leflunomide and anthralin-Potentially undiscovered JAK/STAT inhibitors?
Topics: Administration, Topical; Adolescent; Alopecia Areata; Anthralin; Dermatologic Agents; Hair; Humans; | 2018 |
Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients.
Topics: Administration, Topical; Adolescent; Alopecia Areata; Anthralin; Child; Child, Preschool; Dermatolog | 2018 |
Efficacy of topical dithranol (Dithrocream
Topics: Administration, Topical; Adult; Alopecia Areata; Anthralin; Child; Dermatologic Agents; Drug Adminis | 2019 |
Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series.
Topics: Administration, Topical; Adolescent; Adult; Alopecia Areata; Anthralin; Child; Cyclopropanes; Dermat | 2019 |
Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin.
Topics: Administration, Topical; Adolescent; Adult; Alopecia Areata; Anthralin; Child; Child, Preschool; Chr | 2019 |
Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Alopecia Areata; Anthralin; Apoptosis; CD4-CD8 R | 2015 |
Guidelines for the management of alopecia areata.
Topics: Alopecia Areata; Anthralin; Counseling; Evidence-Based Medicine; Glucocorticoids; Humans; Immunother | 2003 |
Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin.
Topics: Administration, Topical; Alopecia Areata; Animals; Anthralin; Anti-Inflammatory Agents; Cytokines; D | 2004 |
Does DNCB therapy potentiate epicutaneous sensitization to non-related contact allergens?
Topics: Adolescent; Adult; Alopecia Areata; Anthralin; Child; Dermatitis, Contact; Dinitrochlorobenzene; Dru | 1981 |
[Dinitrochlorobenzene treatment of alopecia areata].
Topics: Adolescent; Adult; Alopecia Areata; Anthracenes; Anthralin; Child; Dermatitis, Contact; Dinitrochlor | 1980 |
Evidence-based treatment of alopecia areata.
Topics: Administration, Oral; Administration, Topical; Alopecia Areata; Anthralin; Anti-Inflammatory Agents; | 2001 |
Treatment of alopecia areata by anthralin-induced dermatitis.
Topics: Adolescent; Adult; Aged; Alopecia Areata; Anthracenes; Anthralin; Child; Drug Eruptions; Female; Hum | 1979 |
Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin.
Topics: Administration, Topical; Adolescent; Adult; Alopecia Areata; Anthralin; Child; Drug Combinations; Dr | 1990 |
[Alopecia areata in children].
Topics: Adrenal Cortex Hormones; Alopecia Areata; Anthralin; Autoimmune Diseases; Child; Dermatitis, Atopic; | 1987 |